Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Investors Pump $257M Into Thrive’s Liquid Biopsy Test

Executive Summary

Thrive is developing CancerSEEK, a liquid biopsy test designed to detect cancers at earlier stages of disease.

You may also be interested in...



AACR 2020: Liquid Biopsy Company Guardant Health Presents Colorectal Cancer Data, Outlines Plans For Regulatory Approval

Guardant Health presented new clinical data at this week’s American Association for Cancer Research conference and outlined its growth plans as cancer testing volumes recover after the pandemic.

Breakthrough Status, Big Investments For Liquid Biopsies

The growth potential of liquid biopsy diagnostics is drawing increasing attention, with several recent breakthrough device designations from the US FDA, big funding rounds, and major acquisitions all in play.

Qiagen’s Ambitions: Standing Alone And Strengthening Infectious Disease Portfolio

Qiagen official Antoine Marchal outlines how NeuModx will strengthen its position in the infectious disease space.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT142496

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel